Compare ONL & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONL | ORMP |
|---|---|---|
| Founded | 2021 | 2002 |
| Country | United States | United States |
| Employees | 40 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.5M | 104.6M |
| IPO Year | N/A | N/A |
| Metric | ONL | ORMP |
|---|---|---|
| Price | $2.06 | $2.73 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 284.6K | 232.2K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | N/A | ★ 838.25 |
| EPS | N/A | ★ 1.03 |
| Revenue | ★ $149,775,000.00 | $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.62 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.46 | $1.82 |
| 52 Week High | $4.25 | $3.09 |
| Indicator | ONL | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 30.80 | 57.90 |
| Support Level | $1.92 | $2.66 |
| Resistance Level | $2.31 | $2.84 |
| Average True Range (ATR) | 0.10 | 0.15 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 26.53 | 49.10 |
Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.